Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Increased by AIA Group Ltd

AIA Group Ltd grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 45.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,217 shares of the biopharmaceutical company's stock after acquiring an additional 8,789 shares during the quarter. AIA Group Ltd's holdings in Alnylam Pharmaceuticals were worth $7,761,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC raised its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in Alnylam Pharmaceuticals by 47.4% during the first quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company's stock valued at $415,000 after buying an additional 892 shares during the period. Nordea Investment Management AB lifted its holdings in Alnylam Pharmaceuticals by 3.3% during the first quarter. Nordea Investment Management AB now owns 8,980 shares of the biopharmaceutical company's stock worth $1,365,000 after buying an additional 290 shares during the period. Empowered Funds LLC increased its holdings in shares of Alnylam Pharmaceuticals by 3.9% in the 1st quarter. Empowered Funds LLC now owns 13,849 shares of the biopharmaceutical company's stock valued at $2,070,000 after acquiring an additional 524 shares during the period. Finally, Illinois Municipal Retirement Fund bought a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth $3,942,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded up $5.21 during midday trading on Friday, reaching $277.43. 848,333 shares of the company traded hands, compared to its average volume of 872,291. The company has a fifty day moving average price of $273.88 and a 200 day moving average price of $229.34. The firm has a market capitalization of $35.78 billion, a price-to-earnings ratio of -105.73 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the prior year, the firm earned $1.15 EPS. The company's revenue for the quarter was down 33.3% compared to the same quarter last year. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.67 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the company's stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares of the company's stock, valued at $20,563,480. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ALNY shares. Royal Bank of Canada reiterated an "outperform" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research report on Monday, August 26th. Needham & Company LLC reiterated a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Scotiabank upped their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a "sector outperform" rating in a report on Friday, November 1st. Finally, Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Six analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $294.50.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.